Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17877345 | 0.90 | PARP1 (0.34) | PARP1HDAC8MEN1KMT2APTPN1 | |
| SCHEMBL17868252 | 0.88 | PTPN1 (0.43) | PARP1HDAC8PTPN1NR1H2 | |
| SCHEMBL17877350 | 0.88 | PARP1 (0.34) | PARP1HDAC8MEN1KMT2APTPN1 | |
| SCHEMBL17868159 | 0.78 | PTPN1 (0.43) | PARP1HDAC8PTPN1NR1H2 | |
| SCHEMBL17877360 | 0.77 | PARP1 (0.35) | PARP1MEN1KMT2ANR1H2 | |
| SCHEMBL17868203 | 0.77 | PARP1 (0.35) | PARP1MEN1KMT2ANR1H2 | |
| SCHEMBL17868204 | 0.77 | PARP1 (0.35) | PARP1MEN1KMT2ANR1H2 | |
| SCHEMBL17877349 | 0.74 | BRD4 (0.44) | HDAC8NR1H2 | |
| SCHEMBL17877351 | 0.72 | PTPN1 (0.32) | PARP1PTPN1NR1H2 | |
| SCHEMBL15829069 | 0.72 | CHRM2 (0.39) | HDAC8PTPN1NPC1NR1H2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | NOVIRA THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9550779-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158691-A1 | Derivatives And Methods Of Treating Hepatitis B Infections | HAVCR2, PYGL, HCCS | PARP1 3072/4885HDAC8 1141/4885MEN1 4414/4885 |
| US-20160185779-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | PARP1 3072/4885HDAC8 1141/4885MEN1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.